

Editorial

- Will Single-Time Tumor Profiling and a “Guilt by Association” Approach Allow Us to Outsmart HER2-Positive Breast Cancer?**
 Commentary on Harris et al., p. 1198
 Carlos L. Arteaga 1071

The Biology Behind

- New Practices in Computational Modeling.**
 Commentary on Hu et al., p. 1278
 William R. Greco 1074

Molecular Pathways

- Nuclear Factor- κ B in Development, Prevention, and Therapy of Cancer.**
 Carter Van Waes 1076
- Prospect of Targeting the CD40 Pathway for Cancer Therapy.**
 Robert H. Vonderheide 1083

Reviews

- Important Therapeutic Targets in Chronic Myelogenous Leukemia.**
 Hagop M. Kantarjian, Francis Giles, Alfonso Quintás-Cardama, and Jorge Cortes 1089
- Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions.**
 Brian I. Rini 1098

Human Cancer Biology

- A Susceptibility Gene Set for Early Onset Colorectal Cancer That Integrates Diverse Signaling Pathways: Implication for Tumorigenesis.** Yi Hong, Kok Sun Ho, Kong Weng Eu, and Peh Yean Cheah 1107
- Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of *Plexin B1*.** Achim Rody, Uwe Holtrich, Regine Gaetje, Mathias Gehrman, Knut Engels, Gunter von Minckwitz, Sibylle Loibl, Raihanatou Diallo-Danebrock, Eugen Ruckhäberle, Dirk Metzler, Andre Ahr, Christine Solbach, Thomas Karn, and Manfred Kaufmann 1115
- Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer.** Gabriele D. Maurer, Joerg H. Leupold, Denis M. Schewe, Tobias Biller, Ronald E. Kates, Hans-Martin Hornung, Ulla Lau-Werner, Stefan Post, and Heike Allgayer 1123
- Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma.** Hu-Liang Jia, Qing-Hai Ye, Lun-Xiu Qin, Anuradha Budhu, Marshonna Forgues, Yidong Chen, Yin-Kun Liu, Hui-Chuan Sun, Lu Wang, Hong-Zhou Lu, Fang Shen, Zhao-You Tang, and Xin Wei Wang 1133
- Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation.** Chunrong Yu, Bret B. Friday, Jin-Ping Lai, Andrea McCollum, Peter Atadja, Lewis R. Roberts, and Alex A. Adjei 1140
- Lack of Apoptotic Protease Activating Factor-1 Expression and Resistance to Hypoxia-Induced Apoptosis in Cervical Cancer.** Cornelia Leo, Lars-Christian Horn, Cora Rauscher, Bettina Hentschel, Christine E. Richter, Alexander Schütz, Chandra Paul Leo, and Michael Höckel 1149

Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes. Christos I. Maratheftis, Evangelos Andreacos, Haralampos M. Moutsopoulos, and Michael Voulgarelis 1154

Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Peng Hou, Dingxie Liu, Yuan Shan, Shuiying Hu, Kimberley Studeman, Stephen Condouris, Yangang Wang, Ariel Trink, Adel K. El-Naggar, Giovanni Tallini, Vasily Vasko, and Mingzhao Xing 1161

Imaging, Diagnosis, Prognosis

Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma. Ronny Schuster, Nikolaos E. Bechrakis, Andrea Stroux, Antonia Busse, Alexander Schmittl, Carmen Scheibenbogen, Eckhard Thiel, Michael H. Foerster, and Ulrich Keilholz 1171

Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence. Christian Adrien Righini, Florence de Fraipont, Jean-François Timsit, Claire Faure, Elisabeth Brambilla, Emile Rey, and Marie-Christine Favrot 1179

Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck. Shahnaz Begum, Maura L. Gillison, Theresa L. Nicol, and William H. Westra 1186

Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR. Hideaki Miyake, Isao Hara, Toshifumi Kurahashi, Taka-aki Inoue, Hiroshi Eto, and Masato Fujisawa 1192

Cancer Therapy: Clinical

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. Lyndsay N. Harris, Fanglei You, Stuart J. Schnitt, Agnes Witkiewicz, Xin Lu, Dennis Sgroi, Paula D. Ryan, Steven E. Come, Harold J. Burstein, Beth-Ann Lesnikoski, Madhavi Kamma, Paula N. Friedman, Rebecca Gelman, J. Dirk Iglehart, and Eric P. Winer 1198

Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer. Robert Dreicer, Daniel Petrylak, David Agus, Iain Webb, and Bruce Roth 1208

A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors. Marwan G. Fakih, Donald L. Trump, Josephia R. Muindi, Jennifer D. Black, Ronald J. Bernardi, Patrick J. Creaven, James Schwartz, Michael G. Brattain, Alan Hutson, Renee French, and Candace S. Johnson 1216

Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer. Eleni Efstathiou, Patricia Troncoso, Sijin Wen, Kim-Anh Do, Curtis A. Pettaway, Louis L. Pisters, Timothy J. McDonnell, and Christopher J. Logothetis 1224

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. Robert J. Morgan, Jr., Timothy W. Synold, Bixin Xi, Dean Lim, Stephen Shibata, Kim Margolin, Roderich E. Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Mery Tetef, Paul Lin, Benjamin Paz, Mariana Koczywas, Lawrence Wagman, David Chu, Paul Frankel, Susan Stalter, and James H. Doroshow 1232

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Pamela N. Munster, Carolyn D. Britten, Monica Mita, Karen Gelmon, Susan E. Minton, Stacy Moulder, Dennis J. Slamon, Feng Guo, Stephen P. Letrent, Louis Denis, and Anthony W. Tolcher 1238

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs. Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, and John R. Murren1246

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. James J. Vredenburgh, Annick Desjardins, James E. Herndon II, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, and Henry S. Friedman1253

Cancer Therapy: Preclinical

Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor–Positive Glioma Using Boronated Cetuximab. Gong Wu, Weilian Yang, Rolf F. Barth, Shinji Kawabata, Michele Swindall, Achintya K. Bandyopadhyaya, Werner Tjarks, Behrooz Khorsandi, Thomas E. Blue, Amy K. Ferketich, Ming Yang, Gregory A. Christoforidis, Thomas J. Sferra, Peter J. Binns, Kent J. Riley, Michael J. Ciesielski, and Robert A. Fenstermaker1260

Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin. Constantin Tamvakopoulos, Konstantinos Dimas, Zacharias D. Sofianos, Sophia Hatziantoniou, Zhiyong Han, Zhong-Li Liu, James H. Wyche, and Panayotis Pantazis1269

Computational Modeling to Predict Effect of Treatment Schedule on Drug Delivery to Prostate in Humans. Leijun Hu, Jessie L-S. Au, and M. Guillaume Wientjes1278

CABYR Is a Novel Cancer-Testis Antigen in Lung Cancer. Chonglin Luo, Xueyuan Xiao, Danhui Liu, Shaosong Chen, Mingying Li, Anjian Xu, Jifu Liu, Shugeng Gao, Shanshan Wu, and Dacheng He1288

Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles *In vitro* and *In vivo*. Min Huang, Heyong Gao, Yi Chen, Hong Zhu, Yujun Cai, Xiongwen Zhang, Zehong Miao, Hualiang Jiang, Jian Zhang, Hongwu Shen, Liping Lin, Wei Lu, and Jian Ding1298

Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH₂-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway. Nizar M. Mhaidat, Xu Dong Zhang, Chen Chen Jiang, and Peter Hersey1308

DNA Mismatch Repair Initiates 6-Thioguanine–Induced Autophagy through p53 Activation in Human Tumor Cells. Xuehuo Zeng, Tao Yan, Jane E. Schupp, Yuji Seo, and Timothy J. Kinsella1315

Preclinical *In vivo* Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing’s Sarcoma. Maria C. Manara, Lorena Landuzzi, Patrizia Nanni, Giordano Nicoletti, Diana Zambelli, Pier Luigi Lollini, Cristina Nanni, Francesco Hofmann, Carlos García-Echeverría, Piero Picci, and Katia Scotlandi1322

The Suppression of *Aurora-A/STK15/BTAK* Expression Enhances Chemosensitivity to Docetaxel in Human Esophageal Squamous Cell Carcinoma. Eiji Tanaka, Yosuke Hashimoto, Tetsuo Ito, Kan Kondo, Motoshige Higashiyama, Shigeru Tsunoda, Cristian Ortiz, Yoshiharu Sakai, Johji Inazawa, and Yutaka Shimada1331


Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant. Dingxie Liu, Shuiying Hu, Peng Hou, David Jiang, Stephen Condouris, and Mingzhao Xing1341

Letters to the Editor

Validity of Messenger RNA Expression Analyses of Human Saliva. Jack Ballantyne.....	1350
Salivary Transcriptome. David T. Wong.....	1350
Reply to the Letters to the Editor from Ballantyne and Wong. Simon D. Spivack.....	1351

About the Cover

Chimmitecan is a novel lipophilic camptothecin derivative with improved anticancer pharmacologic profiles compared with the clinical available analogs. Chimmitecan directly interacts with the topoisomerase I-DNA complex, characterized by its outstanding binding affinity. The most probable binding conformation of chimmitecan to the cleavable complex was predicted by automated molecular docking based on the X-ray crystal structure of the topoisomerase I-DNA complex, with topoisomerase I in blue and DNA helices in orange. Residues colored purple represent hydrophobic interaction with the compound and dash line represents hydrogen bond between chimmitecan and topoisomerase I. For further details, please see Huang *et al.* on page 1298 in this issue.



Clinical Cancer Research

13 (4)

Clin Cancer Res 2007;13:1071-1351.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/4>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.